News

Aktis Oncology (NASDAQ:AKTS) rose 8.96% on June 23, 2026, closing at $27.01 after a $2.22 per-share move. The session’s advance came as post-IPO demand sustained oncology stock momentum, based on the available company disclosures and trading context.

CervoMed Inc., a clinical-stage company developing treatments for neuroinflammation-driven Alzheimer's disease, declined on June 23, 2026, as a broad risk-off session weighed on small-cap biotech and clinical-stage names without company-specific catalysts.Key HighlightsCervoMed declined on June 23 alongside the broader small-cap biotech sector during a …

4D Molecular Therapeutics (NASDAQ:FDMT) rose 11.32% on June 23, 2026, closing at $11.60 after a $1.18 per-share move. The session’s advance came as gene therapy momentum fueled a small-cap rebound, based on the available company disclosures and trading context.

Eloxx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, declined on June 23, 2026, as a broad macro risk-off event weighed on small-cap clinical biotechs with no company-specific catalyst associated with the session's move.Key HighlightsEloxx Pharmaceuticals declined on June 23 alongside the broader small-cap biotech sector …

Iovance Biotherapeutics (NASDAQ:IOVA) rose 9.36% on June 23, 2026, closing at $4.44 after a $0.38 per-share move. The session’s advance came as Amtagvi regulatory optimism supported cell-therapy shares, based on the available company disclosures and trading context.

Galectin Therapeutics (NASDAQ:GALT) rose 11.43% on June 23, 2026, closing at $3.12 after a $0.32 per-share move. The session’s advance came as an FDA agreement cleared a path for a Phase 3 MASH trial, based on the available company disclosures and trading context.

Apollomics Inc., a clinical-stage biopharmaceutical company focused on oncology drug development, declined on June 23, 2026, as a broad market risk-off event extended selling pressure across small-cap growth stocks including clinical-stage biotechs with no near-term revenue.